Biocon's European partner Zentiva receives approval from UK MHRA for Liraglutide

Biocon Limited, through its European partner, Zentiva, has received approval from the Medicines and Healthcare Products Regulatory Agency (MHRA), U.K., for its complex formulation Liraglutide (gSaxenda®) in a 6mg/ml solution for injection in pre-filled pen, used in the treatment of Weight Management as an adjunct to a reduced-calorie diet and increased physical activity.

The company had earlier announced about the approval received from the MHRA for Liraglutide (gVicotza®), used in the treatment of Type 2 Diabetes Mellitus, filed through Zentiva.

The approvals will further strengthen Biocon's portfolio of vertically integrated, complex drug products.

Shares of Biocon Limited was last trading in BSE at Rs. 264.10 as compared to the previous close of Rs. 256.60. The total number of shares traded during the day was 1492284 in over 7141 trades.

The stock hit an intraday high of Rs. 266.70 and intraday low of 257.55. The net turnover during the day was Rs. 389362373.00.

Source : Equity Bulls

Keywords

Biocon INE376G01013 Zentiva UK MHRA Approval Liraglutide